QUOIN PHARMACEUTICALS, LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6375 USD | +1.19% |
|
-10.20% | -87.00% |
| Mar. 15 | Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating | MT |
| Mar. 14 | Quoin Pharmaceuticals Seeks M&A Opportunities | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 15.19 | 6.884 | 4.842 | 2.35 | - | - |
| Enterprise Value (EV) 1 | 15.19 | 6.884 | 4.842 | 2.35 | 2.35 | 2.35 |
| P/E ratio | -0.34 x | -0.36 x | -0.51 x | -0.3 x | -0.51 x | -9.11 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 0.15 x | 0.08 x |
| EV / Revenue | - | - | - | - | 0.15 x | 0.08 x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | -3,281,594 x | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 55.7 | 404 | 987 | 3,686 | - | - |
| Reference price 2 | 273.0 | 17.04 | 4.905 | 0.6375 | 0.6375 | 0.6375 |
| Announcement Date | 4/14/22 | 3/9/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 15.58 | 30.54 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -6.063 | -9.258 | -9.378 | -9.409 | -10.23 | -7.528 |
| Operating Margin | - | - | - | - | - | -65.66% | -24.65% |
| Earnings before Tax (EBT) 1 | - | -21.46 | -9.382 | -8.687 | -9.268 | -9.504 | -0.928 |
| Net income 1 | -2.095 | -21.46 | -9.447 | -8.687 | -9.268 | -9.504 | -0.928 |
| Net margin | - | - | - | - | - | -61.02% | -3.04% |
| EPS 2 | -315.0 | -813.0 | -46.80 | -9.640 | -2.150 | -1.250 | -0.0700 |
| Free Cash Flow | - | -4.63 | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 6/16/21 | 4/14/22 | 3/9/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1.303 | -2.981 | -2.176 | -2.668 | -2.328 | -2.086 | -2.776 | -2.26 | -2.125 | -2.218 | -2.256 | -2.296 | -2.337 | -2.378 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -11.82 | -1.683 | -2.668 | -3.03 | -2.001 | -2.603 | -2.107 | -1.927 | -2.05 | -2.256 | -2.296 | -2.337 | -2.378 |
| Net income 1 | -1.404 | -11.82 | -1.683 | -2.668 | -3.095 | -2.001 | -2.603 | -2.107 | -1.927 | -2.05 | -2.256 | -2.296 | -2.337 | -2.378 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -211.5 | 634.5 | -30.00 | -38.88 | -11.28 | -4.955 | -4.080 | -2.130 | -1.950 | -2.080 | -1.110 | -0.4500 | -0.4600 | -0.4700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/20/21 | 4/14/22 | 5/23/22 | 8/18/22 | 11/10/22 | 3/9/23 | 5/9/23 | 8/3/23 | 11/9/23 | 3/13/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -4.63 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 6/16/21 | 4/14/22 | 3/9/23 | 3/13/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.6375
USD
Average target price
5.8
USD
Spread / Average Target
+809.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -87.00% | 2.35M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- QNRX Stock
- Financials Quoin Pharmaceuticals, Ltd.
